Compare Quest Diagnostics Inc (DGX) vs VanEck JP Morgan EM Local Currency Bond ETF (EMLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs VanEck JP Morgan EM Local Currency Bond ETF — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while VanEck JP Morgan EM Local Currency Bond ETF trades at $25.48. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while VanEck JP Morgan EM Local Currency Bond ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, VanEck JP Morgan EM Local Currency Bond ETF nearer its low. Which is the better fit depends on your goals.
| DGX | EMLC | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | Fixed Income |
52-Week High | $216.02 | $26.59 |
52-Week Low | $166.42 | $24.83 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
EMLC trades at $25.39, down 0.63% over 24 hours, with technical indicators signaling a bearish trend. The ETF maintains a consistent dividend payout, with recent distributions of $0.14 per share. News highlights focus on emerging market debt opportunities amid shifting global volatility, though short interest has risen significantly, indicating investor caution.
Outlook remains mixed; EMLC offers attractive yield above Treasuries but faces currency risk and capital erosion concerns. Key risks include Fed policy shifts and emerging market volatility. Institutional demand is growing, yet high short interest suggests skepticism about sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About VanEck JP Morgan EM Local Currency Bond ETF
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →
